哈药集团人民同泰医药股份有限公司 外部信息报送和使用人管理制度 第一章 总 则 第一条 为规范哈药集团人民同泰医药股份有限公司(以下简称 "公司")对外报送相关信息及外部信息使用人使用本公司信息的相 关行为，维护信息披露公平的原则，保证投资者的合法权益，根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准则》 《上市公司信息披露管理办法》《上海证券交易所股票上市规则》等 有关法律、法规及《公司章程》的有关规定，制定本制度。 第二条 本制度所指信息是指所有对公司股票交易价格可能产生 较大影响的未披露信息，包括但不限于定期报告、临时公告、财务数 据、统计数据及正在策划或需要报批的重大事项等。 第三条 本制度的适用范围包括本公司及子公司、分公司、公司 董事、监事、高级管理人员及其他相关内幕信息知情人，公司对外报 送信息涉及的外部单位或个人。 第二章 外部信息报送管理及流程 第四条 公司董事会是信息对外报送的最高管理机构。公司董事 会秘书负责信息对外报送的监管工作，公司董事会办公室负责协助董 事会秘书做好对外报送信息的管理工作，公司各部门、所属分、子公 司和相关人员应按本制度规定履行对外报送信息的审 ...

哈药集团人民同泰医药股份有限公司 董事会秘书工作制度 第一章 总 则 第一条 为进一步提高哈药集团人民同泰医药股份有限公司（以 下简称"公司"）治理水平，完善公司法人治理结构，规范公司董事 会秘书的选任、履职等工作职责，根据《中华人民共和国公司法》（以 下简称《公司法》）《中华人民共和国证券法》《上海证券交易所股票 上市规则》（以下简称《股票上市规则》）等法律法规和其他规范性文 件，特制定本制度。 第二条 公司设董事会秘书一名。董事会秘书为公司高级管理人 员，对公司和董事会负责，应忠实、勤勉地履行职责。 第三条 公司董事会秘书应当承担法律法规及《公司章程》对公 司高级管理人员所要求的义务、享有相应的工作职权。董事会秘书是 公司与上海证券交易所（以下简称"上交所"）之间的指定联络人， 公司设立董事会办公室作为负责管理信息披露事务的部门，董事会秘 书负责分管董事会办公室。 第二章 董事会秘书的任免 第四条 董事会秘书由董事长提名，经董事会聘任或解聘。若原 任董事会秘书离职，则董事会应当在原任董事会秘书离职后 3 个月内 聘任董事会秘书。 第五条 公司董事会秘书应当具备履行职责所必需的财务、管理、 法律等专业知识， ...

一、2023年1-9月主要经营数据 经哈药集团人民同泰医药股份有限公司（以下简称"公司"）财务部门初步 测算，预计公司2023年1-9月营业收入约为76.19亿元到79.82亿元，较上年同期 增长约为5%到10%；预计公司2023年1-9月归属于上市公司股东的净利润约为2.30 亿元到2.49亿元，较上年同期增长约为20%到30%。 证券代码：600829 证券简称：人民同泰 编号：临 2023-022 哈药集团人民同泰医药股份有限公司 2023 年 1-9 月主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上述主要经营数据为初步核算数据，未经注册会计师审计，仅作为阶段性财 务数据供投资者参考，不能以此推算公司全年业绩情况，具体准确的财务数据以 公司后续披露的2023年第三季度报告为准，敬请广大投资者理性投资，注意投资 风险。 二、事项说明 特此公告。 哈药集团人民同泰医药股份有限公司 董事会 二零二三年九月二十七日 ...

证券代码：600829 证券简称：人民同泰 编号：临 2023-021 哈药集团人民同泰医药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2023 年 9 月 5 日（星期二）14:00-15:00 ●会议召开地点：上海证券交易所上证路演中心（https://roadshow.sseinfo.com/） ●会议召开方式：上证路演中心网络互动 ●投资者可于 2023 年 8 月 29 日-9 月 4 日 16:00 前登录上证路演中心网站首页点击"提 问预征集"栏目或将有关问题通过电子邮件的形式发送至公司邮箱： renmintongtai@hyrm tt.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 一、说明会类型 哈药集团人民同泰医药股份有限公司（以下简称"公司"）已于 2023 年 8 月 12 日在《上海证券报》及上海证券交易所网站披露了公司《2023 年半年度报 告》。为进一步加强与投资者的互动交流， ...

一、本公司不存在任何应披露而未披露的影响贵公司股价异常波 动的重大信息,包括但不限于重大资产重组、股份发行、重大交易类 事项、业务重组、股份回购、股权激励、破产重整、重大业务合作、 引讲战略投资者等重大事项。 哈药集团股份有限公司 关于哈药集团人民同泰医药股份有限公司股票交易异常波 动间询网的回复 哈药集团人民同泰医药股份有限公司: 贵公司股票于 2023 年 8 月 15 日、2023 年 8 月 16 日、2023 年 8 月 17 日连续三个交易日内日收盘价格涨幅偏离值累计超过 20%,按 照《上海证券交易所交易规则》的有关规定,属于股票交易异常波动 情况。贵公司发来的《哈药集团人民同泰医药股份有限公司关于股票 交易异常波动的问询函》已收悉。针对函件所列问题,我公司回复如 下: 二、在本次股票交易异常波动期间,本公司不存在买卖贵公司股 票的情况。 特此回复。 本页无正文,为《哈药集团股份有限公司关于哈药集团人民同泰医药 股份有限公司股票交易异常波动问询函的回复》之盖章页: R 公司 T ...

证券代码：600829 证券简称：人民同泰 编号：临 2023-020 哈药集团人民同泰医药股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●哈药集团人民同泰医药股份有限公司（以下简称"公司"）股票于 2023 年 8 月 15 日、 8 月 16 日、8 月 17 日连续 3 个交易日内日收盘价格涨幅偏离值累计超过 20%，属于《上海 证券交易所交易规则》规定的股票交易异常波动情形。 ●经公司自查，并向公司控股股东哈药集团股份有限公司、间接控股股东哈药集团有限 公司核实，不存在应披露而未披露的重大事项或重要信息。 ●敬请广大投资者注意二级市场交易风险，理性投资。 一、股票交易异常波动的具体情况 公司股票于2023年8月15日、8月16日、8月17日连续3个交易日内日收盘价格 涨幅偏离值累计超过20%，根据《上海证券交易所交易规则》的有关规定，属于 股票交易异常波动情况。 二、公司关注并核实的相关情况 （一）经公司自查，公司目前经营活动正常稳健；公司不存在其他应披露而 未披露 ...

哈药集团有限公司 关于人民同泰股票交易异常波动问询函的回复 哈药集团人民同泰医药股份有限公司: 你公司股票交易于 2023年 8 月 15 日、2023 年 8 月 16 日、2023 年 8 月 17 日连续三个交易日内目收盘价格涨幅偏离值累计超过 20%, 按照《上海证券交易所交易规则》的有关规定,属于股票交易异常波 动。你公司发来《哈药集团人民同泰医药股份有限公司关于公司股票 交易异常波动的问询函》已收悉。针对函件所列问题,我公司回复如 下: 一、本公司及公司各方股东不存在任何应披露而未披露的影响你 公司股价异常波动的重大信息,包括但不限于重大资产重组、股份发 行、重大交易类事项、业务重组、股份回购、股权激励、破产重整、 重大业务合作、引进战略投资者等重大事项。 二、我公司在异常波动期间,不存在买卖你公司股票的情况。 特此回复。 本页无正文,为《哈药集团有限公司关于人民同泰股票交易异常波动 问询函的回复》之盖章页: GROUP ITICAL ...

Financial Performance - The company's operating revenue for the first half of 2023 reached ¥5,275,215,855.48, representing a year-on-year increase of 14.57%[24]. - The net profit attributable to shareholders for the same period was ¥153,342,732.01, up 44.81% compared to the previous year[24]. - The net cash flow from operating activities increased significantly by 111.77%, amounting to ¥265,643,607.92[24]. - The total assets of the company at the end of the reporting period were ¥7,417,830,530.61, reflecting a growth of 5.09% from the previous year[24]. - The net assets attributable to shareholders increased by 6.22%, totaling ¥2,617,040,447.33[24]. - The basic earnings per share for the first half of 2023 were ¥0.2644, a rise of 44.80% year-on-year[25]. - The gross profit amounted to 494.46 million RMB, an increase of 7.80 million RMB year-on-year, reflecting the company's proactive adjustments to product structure in response to policy impacts[26]. - The company reported a significant reduction in financial expenses, decreasing from ¥25,431,019.71 to ¥12,721,637.11, a drop of approximately 50%[116]. - The total comprehensive income for the first half of 2023 was 153,342,732.01, with a slight increase of 91,709.39 compared to the previous period[131]. Sales and Market Development - The company has strengthened its sales operations and deepened cooperation with medical institutions, leading to increased sales in both medical and commercial sectors[24]. - The retail segment saw sales growth driven by optimizing product structure and enhancing service quality in community stores[24]. - The DTP professional pharmacy development has been advanced, resulting in increased sales through the introduction of DTP products and improved staff expertise[24]. - The company has successfully completed the renewal of centralized procurement products, contributing to the overall revenue growth[24]. - The wholesale business generated revenue of 4,433.21 million yuan, up 13.73% year-on-year, with 939 new products introduced[47]. - The retail business reported revenue of 763.28 million yuan, marking a 19.43% increase year-on-year, with 982 new products launched[49]. - Membership reached 2.2554 million, with member sales accounting for 72.05% of total sales[49]. - The company aims to expand its market presence and invest in new product development, although specific figures were not disclosed in the report[118]. - The user base has shown a growth rate of 10% year-over-year, indicating strong market demand for its products[130]. Operational Efficiency and Management - The operating cash flow for the reporting period was 265.64 million RMB, an increase of 14.02 million RMB year-on-year, attributed to improved management of accounts receivable and inventory turnover[27]. - The company is focusing on digital transformation and enhancing operational efficiency through strategic project collaborations[45]. - The company is implementing new strategies to improve operational efficiency, targeting a 5% reduction in operational costs by the end of the year[130]. - The company aims to strengthen accounts receivable management to mitigate credit risk and improve cash flow efficiency[67]. Assets and Liabilities - The total current assets amounted to CNY 6,909,465,665.73, an increase from CNY 6,546,377,841.59 at the end of 2022, reflecting a growth of approximately 5.54%[108]. - The cash and cash equivalents stood at CNY 1,232,515,785.68, up from CNY 1,181,469,364.66, indicating an increase of about 4.33%[108]. - Accounts receivable increased to CNY 4,276,850,940.75 from CNY 3,915,687,696.69, representing a rise of approximately 9.23%[108]. - Total liabilities rose to CNY 4,801,759,855.91 from CNY 4,596,080,968.91, indicating an increase of about 4.5%[110]. - The company's equity attributable to shareholders increased to CNY 2,617,040,447.33, up from CNY 2,463,697,715.32, representing a growth of approximately 6.2%[110]. Strategic Initiatives and Future Plans - The company is actively developing DTP specialty pharmacies and online pharmacy services, integrating online and offline operations to enhance customer service[37]. - The company has plans for market expansion and new product development in the upcoming quarters, focusing on enhancing its competitive edge[130]. - The company aims to increase its R&D investment by 15% in the next fiscal year to support innovation and new technology[130]. - The company is exploring potential mergers and acquisitions to strengthen its market position and diversify its product offerings[130]. - The company has set a revenue guidance of 10% growth for the next quarter, driven by new product launches and market strategies[130]. Environmental and Social Responsibility - The company promotes sustainable development and actively responds to national "carbon neutrality" and "carbon peak" policies, focusing on resource utilization and environmental protection[77]. - Measures taken to reduce carbon emissions include strict implementation of food waste reduction laws, water conservation practices, and waste recycling initiatives[78]. Legal and Compliance Matters - The company is involved in a significant lawsuit regarding a construction project, with a court ruling that invalidated certain agreements and ordered the return of property to the company[83]. - The company operates in the pharmaceutical distribution industry and is not classified as a key pollutant discharge unit, adhering to national environmental protection laws without any administrative penalties during the reporting period[76]. Related Party Transactions - The company reported a total of 141,413,200.57 RMB in related party transactions, accounting for 2.82% of total transactions[87]. - The company maintains a market-based pricing policy for transactions with related parties, ensuring no harm to minority shareholders[88]. Corporate Governance - The company has established a governance structure including a shareholders' meeting, board of directors, and supervisory board[151]. - The financial statements for the first half of 2023 were approved by the board on August 11, 2023[151]. - The company adheres to the accounting standards set by the Ministry of Finance and the China Securities Regulatory Commission[153].

证券代码：600829 证券简称：人民同泰 编号：临 2023-017 哈药集团人民同泰医药股份有限公司 关于召开 2022 年度业绩暨现金分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、说明会类型 公司已于 2023 年 3 月 28 日在《上海证券报》及上海证券交易所 网站披露了公司《2022 年年度报告》。为进一步加强与投资者的互动 交流，便于广大投资者更全面深入了解公司经营业绩和利润分配等具 体情况，公司决定参加由黑龙江证监局、黑龙江省上市公司协会与深 圳市全景网络有限公司联合举办的"2023 年黑龙江辖区上市公司投 资者集体接待日暨 2022 年度业绩说明会"。公司将与投资者进行网上 交流，在信息披露允许的范围内就投资者普遍关注的问题进行回答。 会议召开时间：2023 年 5 月 15 日（星期一）下午 14:00-16:30。 会议召开地点："全景路演"网站（http://rs.p5w.net）；或微信公众号（名称： 全景财经）；或全景路演 APP。 会议召开方式：网络远程方式 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 2,653,397,225.81, representing a year-on-year increase of 13.94%[3] - Net profit attributable to shareholders for the same period was CNY 71,786,436.01, reflecting a significant year-on-year growth of 55.62%[6] - The gross profit margin improved to 9.17%, an increase of 0.47 percentage points compared to the previous year, contributing to the rise in net profit[6] - Total operating revenue for Q1 2023 reached CNY 2,653,397,225.81, an increase of 13.9% compared to CNY 2,328,665,371.67 in Q1 2022[19] - Total operating costs for Q1 2023 were CNY 2,550,439,328.97, up from CNY 2,263,690,794.26 in Q1 2022, reflecting a growth of 12.7%[19] - Net profit for Q1 2023 was CNY 72,129,935.24, representing a significant increase of 56.6% from CNY 46,087,379.78 in Q1 2022[20] - Earnings per share (EPS) for Q1 2023 was CNY 0.1238, compared to CNY 0.0795 in Q1 2022, indicating a growth of 55.7%[21] Assets and Liabilities - The total assets at the end of the reporting period were CNY 7,136,692,843.36, up 1.10% from the end of the previous year[4] - The company's total liabilities as of Q1 2023 amounted to CNY 4,601,926,674.82, slightly up from CNY 4,596,080,968.91 in the previous year[17] - The total equity attributable to shareholders reached CNY 2,535,484,151.33, an increase from CNY 2,463,697,715.32 in Q1 2022, marking a growth of 2.9%[17] - The total current liabilities were CNY 4,427,082,345.27, showing a slight decrease from CNY 4,431,327,072.43 in the previous year[17] - The total current assets amounted to approximately RMB 6.63 billion, an increase from RMB 6.55 billion, reflecting a growth of about 1.2%[15] Cash Flow - The company reported a net cash flow from operating activities of -CNY 38,881,437.25, which is not comparable due to the nature of the cash flow[3] - In Q1 2023, the cash inflow from operating activities was CNY 2,535,272,930.90, an increase of 27.2% compared to CNY 1,993,303,465.14 in Q1 2022[22] - The net cash flow from operating activities was CNY -38,881,437.25, slightly improved from CNY -39,018,919.18 in the same period last year[24] - The total cash outflow from operating activities was CNY 2,574,154,368.15, up from CNY 2,032,322,384.32 in Q1 2022, reflecting a 27% increase[24] - The cash and cash equivalents at the end of Q1 2023 amounted to CNY 993,250,103.02, compared to CNY 778,777,950.28 at the end of Q1 2022, marking a 27.5% increase[26] Expenses - The company’s financial expenses decreased by 58.38%, primarily due to the optimization of financing and lower interest expenses[8] - Research and development expenses for Q1 2023 were CNY 6,036,772.45, down from CNY 14,505,000.01 in Q1 2022, indicating a reduction of 58.4%[20] - The company reported a decrease in financial expenses, which were CNY 6,036,772.45 in Q1 2023 compared to CNY 14,505,000.01 in Q1 2022[20] - The company's management expenses increased significantly to CNY 632,284.54 in Q1 2023 from CNY 389,050.95 in Q1 2022, indicating a rise of 62.5%[29] Legal Matters - The company reported a significant legal matter regarding a construction contract dispute, with a previous judgment requiring payment of over RMB 32.55 million, which is currently under review[12][13] - The company has committed to closely monitoring the ongoing legal proceedings and will continue to fulfill its information disclosure obligations[12] Strategic Focus - The company is focusing on expanding its wholesale and retail segments, enhancing brand influence through specialized pharmacies[5] - The company has implemented various measures to improve sales revenue and gross profit margin, leading to a substantial increase in net profit[6] - The company has not disclosed any new product developments or market expansion strategies in the current report[12] - There were no significant updates on mergers or acquisitions during the reporting period[12]